Secondary Logo

Journal Logo

UpToDate®

doi: 10.1097/01.COT.0000528032.62856.71
News
Free

UpToDate® and Oncology Times are collaborating to present select content synopses on “What's New in Oncology.” UpToDate is an evidence-based, clinical support resource used worldwide by healthcare practitioners to make decisions at the point of care. For complete, current ‘What's New’ content, or to become a subscriber for full content access, go towww.uptodate.com. “What's New” abstract information is free for all healthcare practitioners.

Back to Top | Article Outline

Long-Term Outcomes of Women With Breast Cancer and Sentinel Node Metastasis

The American College of Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial established the safety of omitting routine axillary lymph node dissection (ALND) in women with early-stage breast cancer, no palpable axillary adenopathy, and one or two metastatic sentinel lymph nodes. Now, extended follow-up to about 10 years continues to show that both overall survival and disease-free survival after sentinel lymph node dissection (SLND) alone are noninferior to ALND. These results support Z0011's early conclusion that women undergoing breast conserving surgery and SLND do not require routine ALND.

Back to Top | Article Outline

No Incremental Benefit From Robotically Assisted Radical Nephrectomy

Radical nephrectomy is increasingly performed with robotic assistance, despite a lack of evidence of incremental benefit. In a study including over 23,000 patients in a United States database who underwent radical nephrectomy, robotic radical nephrectomy was associated with longer operative time and higher hospital costs than the conventional laparoscopic approach, without lowering the rate of overall or major complications. We suggest conventional laparoscopic surgery for radical nephrectomy; however, robotic assistance may have a role in partial nephrectomy.

Back to Top | Article Outline

Misuse of Prescribed Opioids

Misuse of prescribed opioid drugs is a major source of escalating rates of opioid use disorder and opioid overdose in the United States. The 2015 National Survey on Drug Use and Health estimated that among the 92 million US adults prescribed opioid drugs in the prior year, almost 13 percent reported prescription opioid misuse, and 2 percent reported having a prescription opioid use disorder. Misuse reported by study subjects included taking higher or more frequent doses than prescribed and buying or using opioids prescribed to someone else.

Back to Top | Article Outline

Adjuvant Therapy of Cutaneous Melanoma

Patients at high risk for recurrence after definitive surgical resection of cutaneous melanoma are candidates for adjuvant therapy. In a phase III trial, nivolumab increased relapse-free survival compared with ipilimumab. In another phase III trial, dabrafenib plus trametinib increased relapse-free and overall survival compared with placebo in patients with a BRAF V600 mutation. Neither regimen is currently approved in the adjuvant setting, but enrollment of high-risk patients in formal clinical trials should be considered whenever feasible.

Back to Top | Article Outline

Incidence of Endocrinopathies With Checkpoint Inhibitor Immunotherapy

Immunotherapy of cancer with checkpoint inhibitors is associated with multiple immune-related adverse events, including hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency, and type 1 diabetes. In a systematic review of 38 randomized trials, thyroid dysfunction was the most common endocrinopathy. The combination of nivolumab plus ipilimumab was associated with the highest incidence of hypothyroidism, while monotherapy with a PD-1 inhibitor (nivolumab, pembrolizumab) had the lowest incidence.

Back to Top | Article Outline

New ASCO Guideline Aims to Improve Communication Skills

The way in which serious news is conveyed can substantially influence the emotional response to the news, beliefs and attitudes toward the medical staff, and how patients view their future. While there are no consistent findings from randomized interventional studies that show better patient outcomes after modifying communication skills to deliver serious news, a number of studies have shown that clinician communication skills can be improved by training. A 2017 guideline from the American Society of Clinical Oncology (ASCO) recommends communication skills training for oncologists and presents best practices for core communication skills when clinicians are communicating with patients and their loved ones about goals of care, prognosis, treatment options, and end of life care.

Disclaimer: This content is provided for reference purposes only and represents a portion of the UpToDate topic. You may not rely on the content or any information cited here as being applicable to specific patient circumstances. All topics are updated as new evidence becomes available and our peer review process is complete. Subscribe towww.uptodate.comfor current content and recommendations.

Wolters Kluwer Health, Inc. All rights reserved.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!